Kiran Musunuru of the Perelman School of Medicine, who is a partner in a biotech start-up with labs housed at Pennovation Works, spoke about the potential benefits of CRISPR gene-editing for patients with heart disease. A trial for a similar therapy developed by a different team is currently underway at the Abramson Cancer Center.

June 10, 2019 ・ From Philadelphia Inquirer